Pyridostigmine bromide

Vagotonic, antimyasthenic

Composition

Mestinon contains as active substance the dimethylcarbamic ester of 1-methyl-3-hydroxypyridinium bromide (Pyridostigmine bromide).

Properties

Mestinon possesses cholinergic properties; it belongs to the group of substances which inhibit cholinesterase. It is characterized by the gentle onset, smooth course, comparatively prolonged duration and gradual dying away of its action.

Indications and dosage

Intestinal atony, atonic constipation: 1 dragée 60 mg or 1-2 ampoules 1 mg i.m. as required, e.g. at intervals of four hours.

Myasthenia gravis: 1 - 3 dragées 60 mg two to four times daily; more in severe cases. If required, single doses of 2-5 ampoules s.c. or i.m.

Packs

Tablets 10 mg 50 Dragées 60 mg 20.150

Manufactured by Labiana Pharmaceuticals S.L.U., Barcelona, Spain for



A. Menarini Asia-Pacific Holdings Pte. Ltd.

30 Pasir Panjang Road, #08-32 Mapletree Business City, Singapore 117440

2013MEN-504-1

Pantone Black

IPM No.: 2013MEN-504-1

Product name: Mestinon 60mg 150s dragees insert

Country: HK,SG Version: 2

Date: 27 May 2013